TITLE

Gatifloxacin

AUTHOR(S)
Perry, C.M.; Barman Balfour, J.A.; Lamb, H.M.
PUB. DATE
October 1999
SOURCE
Drugs;Oct1999, Vol. 58 Issue 4, p683
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
▴ Gatifloxacin is a novel extended-spectrum fluoroquinolone with improved Gram-positive and anaerobe coverage compared with older agents such as ciprofloxacin. It has good activity (but is slightly less active than ciprofloxacin) against Enterobacteriaceae. ▴ Gatifloxacin is generally 2- to 4-fold more active than ciprofloxacin against staphylococci, streptococci and enterococci and 4- to 16-fold more active than ciprofloxacin against anaerobes, including Clostridium and Bacteroides spp. ▴ In comparative clinical trials that included patients with lower respiratory tract, urinary tract, skin and soft tissue or gonococcal infections, clinical cure rates of ≥89% were achieved with oral gatifloxacin 400 mg/day for 7 to 14 days. ▴ Data from a subset of North American patients included in a multinational trial showed that oral gatifloxacin 400 mg/day produced a significantly higher clinical cure rate than cefuroxime axetil 250mg twice daily (89 vs 77%; p = 0.01) in patients with acute exacerbations of chronic bronchitis. The clinical efficacy of gatifloxacin was similar to that of clarithromycin or levofloxacin or ceftriaxone (with or without erythromycin) in the treatment of patients with community-acquired pneumonia. ▴ Oral gatifloxacin 400 mg/day showed clinical and bacteriological efficacy similar to that of levofloxacin in patients with skin and soft tissue infections. In patients with urinary tract infections, clinical cure and bacterial eradication rates achieved with a single 400mg oral dose of gatifloxacin were similar to those produced with ciprofloxacin. ▴ In a pooled analysis of tolerability data from trials that included 3021 patients treated with oral gatifloxacin 400 mg/day, the most commonly reported adverse events were nausea (8%), diarrhoea (4%), headache (4%) and dizziness (3%). The drug was reported to be well tolerated. Gatifloxacin does not appear to cause phototoxic effects.
ACCESSION #
9593370

 

Related Articles

  • Clinical Significance of Roseomonas Species Isolated from Catheter and Blood Samples: Analysis of 36 Cases in Patients with Cancer. Do, Indra; Rolston, Kenneth V. I.; Han, Xiang V. // Clinical Infectious Diseases;6/1/2004, Vol. 38 Issue 11, p1579 

    This report analyzes 36 cases of bacteremia or catheter-related infection caused by Roseomonas species, a group of pink, slimy, waterborne, gram-negative coccobadihi. The causative species included the newly described Roseomonas mucosa (22 cases [61%]) and Roseomonas gilardii subspecies rosen (8...

  • European Surveillance of Antimicrobial Consumption (ESAC): outpatient quinolone use in Europe (1997–2009). Adriaenssens, Niels; Coenen, Samuel; Versporten, Ann; Muller, Arno; Minalu, Girma; Faes, Christel; Vankerckhoven, Vanessa; Aerts, Marc; Hens, Niel; Molenberghs, Geert; Goossens, Herman // Journal of Antimicrobial Chemotherapy (JAC);Dec2011 Supplement 6, Vol. 66 Issue suppl_6, pvi47 

    Background Data on more than a decade of outpatient quinolone use were collected from 33 European countries within the European Surveillance of Antimicrobial Consumption (ESAC) project, funded by the European Centre for Disease Prevention and Control (ECDC). Methods For the period...

  • Concentrations of the des-F(6)-quinolone garenoxacin in plasma and joint cartilage of immature rats. Kastner, Michael; Rahm, Ute; Baumann-Wilschke, Irmela; Bello, Akintunde; Stahlmann, Ralf // Archives of Toxicology;Feb2004, Vol. 78 Issue 2, p61 

    Garenoxacin is a des-F(6)-quinolone with a broad antibacterial spectrum, which has previously been shown to exhibit low chondrotoxicity in juvenile dogs compared with several other quinolones. A study was performed to determine whether the low chondrotoxicity observed in immature rats following...

  • Development of a Capillary Electrophoresis Method for the Separation of Fluoroquinolone Derivatives in Acidic Background Electrolyte. Rusu, Aura; Hancu, G.; Gyéresi, Á. // Acta Medica Marisiensis;Jun2014, Vol. 60 Issue 3, p109 

    Introduction: Antibacterial quinolones class comprises a series of synthetic antibacterial agents, following the model of nalidixic acid. Because of their common 6-fl uorosubtituent on the quinolone ring, fluroquinolones are the most potent analogues with extended spectrum of activity and great...

  • Ciprofloxacin.  // Reactions Weekly;5/4/2013, Issue 1451, p15 

    The article presents a case study of a 60-year-old man who developed a bullous fixed drug eruption while receiving ciprofloxacin.

  • Key Role of Mfd in the Development of Fluoroquinolone Resistance in Campylobacter jejuni. Jing Han; Sahin, Orhan; Barton, Yi-Wen; Qijing Zhang // PLoS Pathogens;Jun2008, Vol. 4 Issue 6, p1 

    Campylobacter jejuni is a major food-borne pathogen and a common causative agent of human enterocolitis. Fluoroquinolones are a key class of antibiotics prescribed for clinical treatment of enteric infections including campylobacteriosis, but fluoroquinolone-resistant Campylobacter readily...

  • The potential of liposome–encapsulated ciprofloxacin as a tularemia therapy. Hamblin, Karleigh A.; Wong, Jonathan P.; Blanchard, James D.; Atkins, Helen S. // Frontiers in Cellular & Infection Microbiology;Jun2014, Vol. 4, p1 

    Liposome-encapsulation has been suggested as method to improve the efficacy of ciprofloxacin against the intracellular pathogen, Francisella tularensis. Early work with a prototype formulation, evaluated for use against the F. tularensis live vaccine strain, showed that a single dose of...

  • In vitro and in vivo evaluation of [18F]ciprofloxacin for the imaging of bacterial infections with PET. Langer, Oliver; Brunner, Martin; Zeitlinger, Markus; Ziegler, Sophie; Müller, Ulrich; Dobrozemsky, Georg; Lackner, Edith; Joukhadar, Christian; Mitterhauser, Markus; Wadsak, Wolfgang; Minar, Erich; Dudczak, Robert; Kletter, Kurt; Müller, Markus // European Journal of Nuclear Medicine & Molecular Imaging;Feb2005, Vol. 32 Issue 2, p143 

    Purpose: The suitability of the 18F-labelled fluoroquinolone antibiotic ciprofloxacin ([18F]ciprofloxacin) for imaging of bacterial infections with positron emission tomography (PET) was assessed in vitro and in vivo. Methods: For the in vitro experiments, suspensions of various E. coli strains...

  • US Food and Drug Administration Approval of Ciprofloxacin Hydrochloride for Management of Postexposure Inhalational Anthrax. Meyerhoff, Andrea; Albrecht, Renata; Meyer, Joette M.; Dionne, Peter; Higgins, Karen; Murphy, Dianne // Clinical Infectious Diseases;8/1/2004, Vol. 39 Issue 3, p303 

    In August 2000, the US Food and Drug Administration (FDA) approved ciprofloxacin hydrochloride (Cipro; Bayer) for management of postexposure inhalational anthrax. This was the first antimicrobial drug approved by the FDA for use in treating an infection due to a biological agent used...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics